Observational studyClinical rheumatology2026
Upfront low-dose biosimilar rituximab as first biologic therapy after triple csDMARD failure in seropositive rheumatoid arthritis: a prospective real-world strategy study.
Ashaq Parrey et al.PubMed ↗Publisher ↗
No numbers read from the abstract.